GlassScriptPhysician profile
Emily Abernethy
NPI 1881364859
$1,238.54
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $86.17 · 2022: $910 · 2024: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $242.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $313.99 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $192.99 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.55 | 2024 | Caplyta |
| Axsome Therapeutics, INC. | $116.70 | 2024 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $80.79 | 2022 | |
| Novo Nordisk INC | $76.86 | 2022 | |
| Lilly USA, LLC | $68.89 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $32.37 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.98 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $28.25 | 2022 | |
| Amgen INC. | $26.67 | 2022 | |
| Organon LLC | $25.93 | 2021 | |
| Sobi, INC | $23.46 | 2022 | |
| Sanofi Pasteur INC. | $20.99 | 2022 | |
| Kaleo, INC. | $18.83 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $15.40 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.67 | 2022 | |
| Corium, LLC | $14.03 | 2022 | |
| Merck Sharp & Dohme LLC | $13.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Abernethy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.